Please use this identifier to cite or link to this item:
|Title:||New aspirations: the debate on aspiration pneumonia treatment guidelines.|
|Authors:||Kwong, Jason C;Howden, Benjamin P;Charles, Patrick G P|
|Affiliation:||Austin Health, Heidelberg, Victoria, Australia. email@example.com|
|Citation:||Medical Journal of Australia; 195(7): 380-1|
|Abstract:||Aspiration pneumonia occurs most commonly in patients with a predisposition to aspiration (eg, those with neurological bulbar dysfunction). There is limited evidence regarding the involvement of anaerobes in most cases of aspiration pneumonia. Most patients respond to treatment for aspiration pneumonia without specific anti-anaerobic therapy such as metronidazole. Metronidazole has adverse side effects, and widespread use where not indicated can promote carriage of multiresistant intestinal flora such as vancomycin-resistant enterococci. Use of metronidazole may be appropriate in patients with aspiration pneumonia and evidence of a lung abscess, necrotising pneumonia, putrid sputum or severe periodontal disease.|
|Internal ID Number:||21978335|
|Subjects:||Anti-Infective Agents.therapeutic use|
Practice Guidelines as Topic
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.